U.S. market momentum Nyxoah demonstrates accelerating U.S. adoption of Genio with growing surgeon training, expanding active accounts, and favorable reimbursement discussions, signaling a strong opportunity for field sales to scale partnerships with high-volume centers.

Reimbursement trajectory CMS proposed increases for Genio related procedures suggest improving affordability and economics for customers, making the total cost of ownership more attractive and reducing payer friction for new installations.

Clinical evidence leverage Continued emphasis on best-in-class outcomes and neuromodulation efficacy provides a strong narrative to engage hospital systems and KOLs, enabling targeted outreach to drive referrals, defector prevention, and expanded clinical adoption.

Financial runway Solid quarterly revenue momentum, substantial cash position, and secured financing support a longer sales horizon, allowing teams to pursue multi-site deployments and accelerate coverage in strategic markets.

Expansion readiness Growing pipeline of trained surgeons, activated high-volume sites, and patient submissions under prior authorization indicate readiness for larger procurement deals, channel partnerships, and managed care negotiations.